FDA Watch: New Policy Would Allow DTC Marketing of Genetic Tests without Premarket Approval

Email not displaying correctly? View it in your browser.
  Lab and Pathology Insider Logo  
Dec 5, 2017  
placeholder  INDUSTRY BUZZ
FDA Watch: New Policy Would Allow DTC Marketing of Genetic Tests without Premarket Approval
From - Laboratory Industry Report
For years, the lab industry has been pressing the FDA to relinquish its rigorous oversight of direct-to-consumer (DTC) genetic health tests…
Read More

placeholder  COMPLIANCE CORNER
Medicare Exclusions: One Week, Two Different Labs Get the Boot
From - G2 Compliance Advisor
Exclusion of a clinical lab from participating in Medicare or other government health programs is a relatively rare penalty…
Read More
     


placeholder  TOP OF THE NEWS
Malpractice Lawsuit Calls Out Lack of Genetic Counseling
From - Diagnostic Testing & Emerging Technologies
A 36-year-old Oregon woman filed a $1.8 million medical malpractice lawsuit against her doctors and a southwest Oregon medical center for…
Read More

placeholder  PAMA
CMS Ignores Flawed Processes, Finalizes 2018 PAMA Pricing; Labs Need to Take Immediate Action to Offset Impending Lean Times
From - G2 Blog
The final 2018 clinical laboratory fee schedule (CLFS) is out, and it is evident that the argument that the…
Read More

 


For questions concerning delivery of this email, please contact customer service at:
(888) 729-2315 | customerservice@plainlanguagemedia.com

Copyright © 2017, All rights reserved.
Plain Language Media LLLP
PO Box 509, New London, CT 06320